Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes Biotech

The Future of Manufacturing: How Composites Will Transform Industries

by Team Lumida
July 7, 2024
in Biotech
Reading Time: 3 mins read
A A
0
The Future of Manufacturing: How Composites Will Transform Industries
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. New manufacturing techniques make composites cheaper and more accessible.
  2. Composites promise lighter, stronger consumer products and advanced aerospace components.
  3. Major companies are testing composites to replace traditional metals.

What Happened?

New manufacturing techniques are making composites—materials made from a variety of fibers embedded in plastics—cheaper and more accessible. Historically, composites like carbon-fiber have been limited to high-cost applications such as aerospace due to their labor-intensive manufacturing process.

However, startups such as Arris Composites, 9T Labs, and Orbital Composites are revolutionizing production methods. These companies have developed processes to quickly and inexpensively create composite parts, enabling their use in a wide range of products from running shoes to aerospace components. For example, Arris’s technology is being tested by Airbus to replace metal brackets in planes, and Orbital Composites has contracts with the U.S. military for satellite and drone components.

Why It Matters?

This shift to composites could transform multiple industries. Composites offer lighter and stronger alternatives to metal, significantly impacting transportation, consumer electronics, and even military applications. Imagine lighter, more fuel-efficient vehicles, durable smartphones, and advanced aerospace components—all possible due to these new materials.

“Composites are often able to perform just as well as high-strength metal parts, but with a fraction of the weight,” says Jeff Sloan, publisher of Composites World. This transition also mitigates geopolitical risks tied to metal supply chains, such as those involving titanium from Russia and China. Companies like ST Engineering are already experimenting with composite bolts for airplanes, showing promising initial results.

What’s Next?

Expect more consumer products and industrial applications to incorporate composites. Short-term, you’ll see lighter and more durable consumer electronics and advanced military hardware. Long-term, the automotive and aerospace industries will likely see the most significant transformations, reducing weight and improving efficiency.

Arris is in talks to use composites in virtual reality headsets, and 9T Labs is eyeing bicycle manufacturing. However, widespread adoption will depend on overcoming consumer perceptions associating metal with quality and proving long-term durability through rigorous testing. Investors should watch for announcements from key players like Airbus and U.S. military contractors, as these will signal broader market adoption and potential investment opportunities.

Source: WSJ
Tags: AerospaceCompositesManufacturing
Previous Post

S&P 500’s Big Earnings Test: Will Tech Slowdown Derail Gains?

Next Post

Web3 Goes Mobile: Valora’s Game-Changing Mobile Stack for iOS and Android

Recommended For You

TRex Bio Seeks $133 Million at a $439 Million Valuation With Lilly Buying In Right Up to the 19.9% Threshold

by Team Lumida
5 hours ago
Iambic Therapeutics Files for IPO; Nvidia-Backed AI Drug Discovery Firm Targeting Cancer Treatments; Partners With Abbvie, Takeda; Ticker IAM

Three of the largest pharmaceutical companies sit on the cap table, and the entire valuation rests on one readout due in mid-2027.

Read more

Iambic Therapeutics Files for IPO; Nvidia-Backed AI Drug Discovery Firm Targeting Cancer Treatments; Partners With Abbvie, Takeda; Ticker IAM

by Team Lumida
2 weeks ago
Iambic Therapeutics Files for IPO; Nvidia-Backed AI Drug Discovery Firm Targeting Cancer Treatments; Partners With Abbvie, Takeda; Ticker IAM

Clinical-stage biotech Iambic Therapeutics (founded 2019, $461.8M raised) files for IPO with Nvidia as shareholder. Uses AI to develop early-stage cancer drugs; partnerships with Abbvie, Takeda, Lundbeck.

Read more

ADARx Seeks $371.9 Million at a $1.74 Billion Valuation With AbbVie Taking 4.9% and Losses Running at $48.4 Million a Half

by Team Lumida
2 weeks ago
Study Finds Trump’s Drug-Pricing Push Incentivizes Higher Prices and Reduced Access Outside the US

The San Diego siRNA developer prices September 24, backed by a partner that has already paid it $335 million and now anchors the offering.

Read more

Novo Nordisk Disappoints at Capital Markets Day; Plans 5+ Blockbusters by 2035 But Offers No Specific Growth Targets; Shares Fall 7.7%

by Team Lumida
2 weeks ago
Novo Nordisk Disappoints at Capital Markets Day; Plans 5+ Blockbusters by 2035 But Offers No Specific Growth Targets; Shares Fall 7.7%

Novo targets 150bn DKK ($23bn) pipeline sales by 2035 with 5+ blockbuster launches, but investors wanted more specific growth guidance. Share fell 7.7% on disappointment.

Read more

RFK Jr.-Linked Nonprofit Quoted $300,000 for a Panel Slot and a Private Dinner With Kennedy and Oz

by Team Lumida
2 weeks ago
RFK Jr.-Linked Nonprofit Quoted $300,000 for a Panel Slot and a Private Dinner With Kennedy and Oz

Bloomberg reports a MAHA Summit sponsorship menu sold access to HHS officials, with sponsors including Grail, ResMed, UnitedHealth and Compass Pathways.

Read more

Study Finds Trump’s Drug-Pricing Push Incentivizes Higher Prices and Reduced Access Outside the US

by Team Lumida
3 weeks ago
Study Finds Trump’s Drug-Pricing Push Incentivizes Higher Prices and Reduced Access Outside the US

A Lancet study found that for roughly three in four drugs studied, matching US Medicare prices to cheaper reference countries would cost companies more than they earn in...

Read more

AstraZeneca’s Etcamah Misses Statistical Significance in First-Line Breast Cancer Trial, Days After FDA Approval

by Team Lumida
3 weeks ago
AstraZeneca’s Etcamah Misses Statistical Significance in First-Line Breast Cancer Trial, Days After FDA Approval

AstraZeneca's Etcamah, paired with Pfizer's Ibrance, showed only a numerical benefit against advanced breast cancer, falling short of significance a week after winning FDA approval on separate trial...

Read more

Ipsen Weighs Return to US Manufacturing as Tariff Pressure Pulls European Drugmakers Onshore

by Team Lumida
3 weeks ago
Ipsen Weighs Return to US Manufacturing as Tariff Pressure Pulls European Drugmakers Onshore

French drugmaker Ipsen is considering a US production site for Dysport or a next-generation successor, joining AstraZeneca, Roche, UCB and CSL in onshoring plans.

Read more

U.S. Risks Losing Biotech Leadership to China, Congressional Report Warns

by Team Lumida
1 year ago
woman holding test tubes

Key Takeaways: Powered by lumidawealth.com A congressional commission has urged the U.S. to invest at least $15 billion in biotechnology research and manufacturing over the next five years to...

Read more

AstraZeneca Acquires EsoBiotec for $1 Billion to Strengthen Cell-Therapy Portfolio

by Team Lumida
2 years ago
vitamin b 12 100 mg

Key Takeaways: Powered by lumidawealth.com AstraZeneca will pay $425 million upfront, with an additional $575 million tied to milestones. The acquisition includes EsoBiotec’s innovative in vivo cell therapy platform....

Read more
Next Post
Web3 Goes Mobile: Valora’s Game-Changing Mobile Stack for iOS and Android

Web3 Goes Mobile: Valora's Game-Changing Mobile Stack for iOS and Android

$2.1 Trillion Private Credit Market Faces Major Risk: Are Investors Safe?

$2.1 Trillion Private Credit Market Faces Major Risk: Are Investors Safe?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Coinbase Q2 2024 Earnings Highlights: Diversification Drives Sixth Consecutive Quarter of Positive Adjusted EBITDA

Coinbase Q2 2024 Earnings Highlights: Diversification Drives Sixth Consecutive Quarter of Positive Adjusted EBITDA

August 2, 2024
Apple Loses Key Home Hardware Leader to Oura, Deepening Smart Home Struggles

Apple Loses Key Home Hardware Leader to Oura, Deepening Smart Home Struggles

March 18, 2026
September Rate Cut Likely as Job Market Risks Increase, Says Fed

Looser Fed Capital Rules Could Hand Big Banks a Massive New Stimulus

March 17, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018